Preliminary Results for the Year Ended 31 December 2023
GlobeNewswire
19 April 2024
*Biodexa Pharmaceuticals PLC*
(“Biodexa” or the “Company” or, together with its subsidiaries,..
19 April 2024
*Biodexa Pharmaceuticals PLC*
(“Biodexa” or the “Company” or, together with its subsidiaries,..
*Revenue of $60.6 million including $12.6 million from Managed Services*
* Net Income of $6.2 million and Adjusted..
· Initiated limited U.S. commercial launch of the Pure-Vu^® EVS Gastro and Gen 4 Colon system, including successful UGI..